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Abstract
Gastrointestinal cancer is a group of tumors that affect 
multiple sites of the digestive system, including the 
stomach, liver, colon and pancreas. These cancers 
are very aggressive and rapidly metastasize, thus 
identifying effective targets is crucial for treatment. 
Galectin-1 (Gal-1) belongs to a family of glycan-binding 
proteins, or lectins, with the ability to cross-link specific 
glycoconjugates. A variety of biological activities 
have been attributed to Gal-1 at different steps of 
tumor progression. Herein, we summarize the current 
literature regarding the roles of Gal-1 in gastrointestinal 
malignancies. Accumulating evidence shows that 
Gal-1 is drastically up-regulated in human gastric 
cancer, hepatocellular carcinoma, colorectal cancer 
and pancreatic ductal adenocarcinoma tissues, both 
in tumor epithelial and tumor-associated stromal cells. 
Moreover, Gal-1 makes a crucial contribution to the 
pathogenesis of gastrointestinal malignancies, favoring 
tumor development, aggressiveness, metastasis, 
immunosuppression and angiogenesis. We also 
highlight that alterations in Gal-1-specific glycoepitopes 
may be relevant for gastrointestinal cancer progression. 
Despite the findings obtained so far, further functional 
studies are still required. Elucidating the precise 
molecular mechanisms modulated by Gal-1 underlying 
gastrointestinal tumor progression, might lead to the 
development of novel Gal-1-based diagnostic methods 
and/or therapies.
Key words: Galectin-1; Gastric cancer; Hepatocellular 
carcinoma; Colorectal carcinoma; Pancreatic cancer; 
β1,6-N-acetylglucosaminyltransferase V
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Core tip: Gastrointestinal cancer is a group of tumors 
that affect multiple sites of the digestive system, including 
the stomach, liver, colon and pancreas. Galectin-1 (Gal-1) 
is a β-galactoside-binding protein with the ability to cross-
link specific glycoconjugates. Accumulating evidence 
shows that Gal-1 in human gastric cancer, hepatocellular 
carcinoma, colorectal cancer and pancreatic ductal 
adenocarcinoma tissues is up-regulated. Moreover, high 
levels of this galectin correlate with tumor development, 
aggressiveness, metastasis, immunosupression and 
angiogenesis. We also highlight that alterations in Gal-1-
specific glycoepitopes may be relevant for gastrointestinal 
cancer progression.
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INTRODUCTION
Gastrointestinal cancer is the most common group of 
malignancies. It refers to tumors developed at multiple 
sites of the gastrointestinal tract, including stomach, 
liver, colon and pancreas. During the past decade, 
advances in molecular medicine have led to improve 
prevention, diagnosis and therapy. Nevertheless, 
most of these cancers are very aggressive and rapidly 
metastasize and therefore, they are among the most 
deadly[1]. Thus, the identification of new molecular 
targets is crucial to develop more effective therapeutic 
strategies.
Galectins are proteins that decode and interpret 
the glycome. This is a family of glycan-binding proteins 
(lectins) with affinity for β-galactoside-containing 
N-glycans[2]. This affinity for N-glycans increases in 
proportion to β1-6 branching, which is mediated by 
the β1,6-N-acetylglucosaminyltransferase V (GnTV)[3] 
and extension with poly-N-acetyllactosamine[4]. 
Interestingly, the altered expression of galectins is 
considered a hallmark of cancer and mounting evidence 
illustrates their fundamental roles in tumor biology[5,6]. 
Besides, important changes in glycosylation occur 
during tumorigenesis and metastasis, including the 
increase in N-glycan size in several cancer-associated 
glycoproteins[7].
One member of this family is galectin-1 (Gal-1), 
which possesses specific structural features. It is 
secreted from cells and is able to bind and cross-link 
glycoconjugates on cell surfaces, including different 
integrins and glycoproteins of the extracellular matrix 
(ECM)[8]. Consequently, Gal-1 modulates cell adhesion, 
migration, survival and signaling[9]. Intracellularly, 
Gal-1 interacts with the RAS binding domain of RAF 
effectors and increases H-RAS nanoclustering driving 
tumor transformation[10]. Gal-1 expression is frequently 
increased in tumor tissues[11,12]. Elevated levels of 
Gal-1 secreted to the extracellular space of tumor and 
tumor-associated stromal cells, often correlate with 
tumor aggressiveness and acquisition of a metastatic 
phenotype[13]. This lectin also plays fundamental roles 
in tumor angiogenesis by modulating endothelial cell 
biology[14-16] and contributes to tumor immunoevasive 
programs[17]. Given these tumor-promoting activities, 
Gal-1 is considered a potential target for cancer 
therapy[13].
Important roles of some members of the galectin 
family have been described in gastrointestinal tumors[18-22]. 
In this review, we summarize the current knowledge 
regarding the expression and roles of Gal-1 in gast-
rointestinal malignancies, focusing on gastric cancer, 
hepatocellular carcinoma, colorectal carcinoma and 
pancreatic cancer. We also highlight that alterations 
in Gal-1-specific glycoepitopes may be relevant for 
gastrointestinal cancer progression. Our aim is to 
encourage researchers to continue exploring the 
complex roles of Gal-1 in gastrointestinal tumors. We 
are confident that basic and translational research 
in this field will lead to the development of Gal-1-
targeted therapies for gastrointestinal cancer patients 
in the future. 
ROLES OF GAL-1 IN GASTRIC CANCER
Gastric cancer (GC) ranks second for cancer deaths[1]. 
Most of these cancers are adenocarcinomas, which are 
subdivided into intestinal or diffuse types. In intestinal-
type cancer, tumor cells exhibit intercellular adhesion 
and are arranged in tubular structures[23]. By contrast, 
in the diffuse type, tumor cells are poorly cohesive 
and infiltrate the stroma as small subgroups[23,24]. 
Although these subtypes are biological, clinical and 
epidemiologically different, in clinical practice this 
classification is not useful for predicting treatment 
response or survival[23]. Besides, according to the 
anatomical location, adenocarcinomas are classified as 
proximal and distal.
Risk factors for proximal GC include increased body 
weight, gastro-esophageal reflux disease and Barrett’s 
esophagus, while chronic infection with Helicobacter 
pylori (H. pylori) is the strongest risk factor for distal 
GC[25,26]. Besides, gene amplification of human epithelial 
growth factor receptor 2 (HER2), a proto-oncogene, is 
found in approximately 17% of GC samples[27].
GC is often diagnosed at advanced stages and 
therapy includes surgery with adjuvant chemotherapy 
or chemoradiation. Advances in the understanding of 
the molecular profiling of GC led to the development of 
trastuzumab and ramucirumab, humanized monoclonal 
antibodies anti-HER2 and anti-vascular endothelial 
growth factor receptor 2 (VEGFR-2), respectively[28]. 
However, the median survival at advanced stage is 
less than 1 year, pointing out the need to identify new 
molecular targets and biomarkers[29].
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In this section we summarize the available knowledge of 
Gal-1 expression in GC and its contribution to progression. 
Gal-1 expression in human GC tissues, correlation 
with clinicopathological parameters and prognostic 
significance
One of the main features of intestinal-type GC is 
chronic inflammation, which leads to precancerous 
lesions. High Gal-1 immunostaining was observed 
in premalignant chronic gastritis, gastric ulcer and 
intestinal metaplasia lesions, both in epithelium 
and stroma, suggesting Gal-1 involvement in gastric 
carcinogenesis[30,31]. In addition, Gal-1 overexpression 
in gastric adenocarcinoma tissues vs normal mucosa 
was reported[30-34]. Gal-1 was highly expressed in tumor-
associated stromal cells and weakly expressed in cancer 
epithelial cells. Interestingly, Gal-1 staining intensity 
in tumor-associated stroma significantly correlated 
with tumor location, invasion, differentiation, tumor 
stage and lymph node metastasis[32,33,35-37]. Moreover, 
patients with high stromal Gal-1 expression exhibited 
a lower five-year survival rate respect to patients with 
low expression[32,33,37]. 
Although low Gal-1 expression in cancer epithelial 
cells in intestinal-type GC was observed, this galectin 
was detected in tumor cells of signet ring cell carcinoma 
(SRCC), a diffuse type of gastric carcinoma[38]. These 
differences could be explained by the specific SRCC 
oncogenesis which differs from that of tubular gastric 
adenocarcinoma[39].
A crucial step during cancer progression is epithelial-
mesenchymal transition (EMT), which involves changes in 
cell-cell and cell-matrix interactions and cell motility, allowing 
tissue epithelial cancers to invade and metastasize[40]. 
During EMT, tumor cells change their epithelial cell 
morphology toward a fibroblastoid phenotype, being 
this process favored by the downregulation of epithelial 
cell markers and the up-regulation of mesenchymal 
markers. In GC, EMT is regulated through activation of 
glioma-associated oncogene 1 (Gli1), a key member of 
the Hedgehog (Hh) signaling pathway. The adherens 
protein E-cadherin is an epithelial marker which 
expression and localization are frequently deregulated 
in GC. It was found that Gal-1 expression in GC tissues 
was positively correlated with Gli-1 and vimentin (a 
mesenchymal cell marker) expression but negatively 
associated with E-cadherin expression[36,37]. 
Furthermore, Gal-1 was positively associated with 
VEGF, suggesting that both molecules can serve as 
indicators of poor prognosis for GC patients[32,41]. 
Cancer-associated fibroblasts (CAFs), one of the major 
components of tumor stroma, contribute to cancer cell 
proliferation, invasion and metastasis. A potent inducer 
of fibroblast transformation into CAFs is transforming 
growth factor beta 1 (TGF-β1), a cytokine elevated in 
tumor microenvironments. Interestingly, increased 
levels of Gal-1 were observed in CAFs isolated from 
GC patient tissues compared to fibroblasts from 
adjacent normal mucosa (NFs)[33,34,41]. Also, a positive 
correlation between Gal-1 and TGF-β1 in GC tissues 
was described[33]. Moreover, Gal-1 expression in CAFs 
correlated with β 1 integrin expression in GC tissues[34]. 
This integrin is a cell adhesion receptor with various 
functions in cancer biology, such as proliferation, 
invasion and migration. Staining intensities of both β 1 
integrin and Gal-1 were associated with lymph node 
and distant metastasis and tumor/node/metastasis 
(TNM) stage of clinicopathological parameters. Strong 
intensity of double positive samples was associated 
with poor prognostic and low survival[34]. 
Therefore, elevated Gal-1 levels in GC tissues, mainly 
in stromal cells, are associated with tumor progression 
(Figure 1). Besides, Gal-1 expression may be related 
to EMT and metastasis. Further studies are required to 
confirm the usefulness of Gal-1 as a prognostic factor for 
GC.
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Gal-1 in hepatocellular carcinoma
Up-regulated, mainly in stroma
Correlates with tumor size, TNM
stage, invasion, metastasis, 
recurrence, poor survival
Increased levels in serum correlate 
with poor survival and reduced 
sorafenib treatment efficacy
Gal-1 in colorectal cancer
Up-regulated, mainly in stroma
Correlates with invasion, lymph 
node metastasis, poor survival
Increased levels in serum correlate 
with tumor stage, liver and lymph 
node metastasis
Gal-1 in gastric cancer
Up-regulated, mainly in stroma
Correlates with TNM stage, invasion, lymph 
node metastasis, poor survival
Gal-1 in pancreatic cancer
Up-regulated, mainly in stroma
Correlates with tumor size, TNM stage, invasion, 
lymph node metastasis, poor survival
Figure 1  Galectin-1 expression in gastrointestinal tumors and correlation with clinicopathological parameters. Galectin-1 is drastically up-regulated in 
human gastric cancer, hepatocellular carcinoma, colorectal cancer and pancreatic ductal adenocarcinoma tissues, mainly in stroma. High levels of Gal-1 correlate 
with tumor aggressiveness, the acquisition of a metastatic phenotype and patient poor survival. TNM: Tumor/node/metastasis; Gal-1: Galectin-1. 
Bacigalupo ML et al . Galectin-1 in gastrointestinal malignancies
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the up-regulation of Gli1[37] and the invasion-promoting 
effect of CAF-derived Gal-1[34]. These results suggest 
an essential role of β 1 integrin in the Gal-1-induced 
EMT and metastasis in GC. Moreover, high expression 
of Gal-1 in gastric CAFs increased human umbilical 
vein endothelial cell proliferation, migration, tube 
formation and VEGFR-2 phosphorylation[41]. 
The immunosuppressive transcription factor FoxP3 was 
found to be expressed not only in regulatory T cells (Tregs) 
but also in SRCC tissues. Remarkably, Gal-1 expression 
was downregulated when FoxP3 was silenced in SRCC-
derived OCUM-2M cells[38]. These findings suggest that 
FoxP3 expressed both in Tregs and SRCC tumor tissues 
may be important for Gal-1 tumor expression, which may 
subsequently induce immunosuppression.
As Gal-1 is a glycan-binding protein, alterations in 
the glycosylation pattern of its ligands within tumor 
microenvironment may affect galectin functions. For 
example, GnTV deficiency prevented Gal-1 binding 
to endothelial cells and decreased tumor growth by 
attenuating aberrant vascularization[46]. Particularly 
in GC, diverse alterations in cell glycosylation pattern 
modulate tumor cell behavior. GnTV overexpression 
in GC contributes to cell invasion and metastasis[47-49]. 
Interestingly, GnTV up-regulation in MKN45 GC cells 
induced cell migration mediated by α3β1 integrin 
glycosylation[50] and EMT involving E-cadherin glyco-
sylation[51]. Thus, not only an alteration in Gal-1 protein 
levels but also the aberrant glycosylation pattern of 
its ligands, such as integrins, may contribute to GC 
progression.
Thus, Gal-1 has a relevant role in the crosstalk between 
GC and stromal cells, favoring tumor cell proliferation, 
EMT and dissemination and angiogenesis (Figure 2). 
Altogether, these findings point that Gal-1 regulates 
key steps during GC progression. 
ROLES OF GAL-1 IN HEPATOCELLULAR 
CARCINOMA 
Hepatocellular carcinoma (HCC), the most common type 
of liver cancer, is the third cause of cancer-related deaths. 
Risk factors include chronic hepatitis B or C virus infection, 
alcohol abuse and non-alcoholic fatty liver disease[52]. 
HCC usually develops in the background of chronic liver 
inflammation, advanced fibrosis and cirrhosis[53]. Thus, 
it arises not only as a consequence of the molecular 
changes that occur in transformed hepatocytes, but also 
due to the crosstalk between diverse cells and molecules 
within tumor microenvironment[54].
During the past decade new advances led to an earlier 
detection of HCC[55]. Additionally, current therapies such 
as, resection, transplantation and chemoembolization, 
benefit patients diagnosed at early HCC stages improving 
and extending their survival[56,57]. However, most patients 
are diagnosed at advanced stages and therefore, they 
are not amenable to surgery. Even after resection or 
transplantation, the prognosis remains unsatisfactory 
Gal-1 contribution to GC development and angiogenesis 
in experimental models
The administration of N-methyl-N´-nitro-N-nitro-
soguanidine (MNNG), a carcinogen that destroys 
stomach mucous barrier, constitutes a rat GC model in 
which animals develop benign and malignant lesions 
with an inflammatory cell-enriched stroma[42]. Enteric 
nervous system regulates immune and inflammatory 
processes thus, chemical myenteric denervation 
reduces MNNG-induced GC incidence[43]. Remarkably, 
Gal-1 was highly expressed in nondenervated-rat 
stomachs, whereas chemical myenteric denervation 
downregulated Gal-1 expression[42]. Thus, the decrease 
in Gal-1 levels had a protective role in this model, 
associated with a reduced density of inflammatory 
cells. 
Further, the role of CAF-derived Gal-1 in tumor 
growth and angiogenesis was studied using the chick 
embryo chorioallantoic membrane (CAM) assay[41]. NFs 
or CAFs obtained from human samples were co-cultured 
with SGC7901 GC cells and injected into CAMs. Also, 
Gal-1 was overexpressed or silenced in CAFs. Both tumor 
volume and number of blood vessels were significantly 
higher with Gal-1-overexpressing CAFs respect to control 
CAFs and NFs[41]. 
These results suggest that Gal-1 participates in the 
development of experimental GC and that CAF-derived 
Gal-1 promotes gastric tumor growth and angiogenesis 
(Figure 2).  
Molecular mechanisms associated with GC progression 
induced by Gal-1
Studies in human tissues suggest an association 
between Gal-1 expression and EMT in GC. Interestingly, 
the expression of cell adhesion-related genes in H. 
pylori-infected AGS GC cells was analysed by cDNA 
microarray. It was found that Gal-1 and α 5 integrin 
genes were up-regulated, whereas E-cadherin gene was 
downregulated, compared to cells without infection[44]. 
Furthermore, Gal-1, β -catenin, vimentin, α 6 and β 4 
integrin expression was elevated in high metastatic 
GC cell lines compared with low metastatic cells[36,45]. 
Besides, Gal-1 overexpression in MKN-74 low invasive 
cells decreased E-cadherin and increased Gli1 levels, 
activating Hh pathway and favoring cell invasion[36]. 
Further, the role of Gal-1 in the interaction between 
GC and stromal cells was studied. TGF-β1 secreted 
by MKN7 GC cells up-regulated Gal-1 in NFs in a 
phosphoinositide 3-kinase (PI3K)/AKT-dependent 
manner. Interestingly, Gal-1 induced the expression 
of α-smooth muscle actin (α-SMA, a myofibroblast 
marker) favoring transformation from NFs to CAFs[33]. 
Besides, CAF-derived Gal-1 inhibited apoptosis and 
promoted EMT, migration and invasion of several 
GC cell lines, decreasing E-cadherin expression but 
enhancing vimentin, Gli1[37], matrix metallopeptidase 
(MMP) 9[33], β 1 integrin[34] and VEGF[41] expression. 
Moreover, silencing β 1 integrin in GC cells prevented 
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due to recurrence, metastasis and the development of 
new primary tumors[58,59].
Recent progress toward a better understanding of HCC 
has shed light on new molecular targeted and systemic 
therapies. Sorafenib, a multikinase inhibitor targeting VEGF, 
platelet-derived growth factor and RAF signaling pathways, 
prolongs survival in patients with advanced unresectable 
HCC[60,61]. Despite the modest increase in survival[60], 
undoubtedly the approval of oral administration of 
sorafenib highlights the importance of elucidating the 
molecular mechanisms underlying HCC progression for 
the development of novel therapies.
Here we review the accumulating evidence that points 
towards a remarkable role of Gal-1 in HCC progression, 
aggressiveness and metastasis. 
Gal-1 expression in human HCC tissues, correlation with 
clinicopathological parameters and prognostic value
While in human normal or adjacent non-tumor liver 
tissues Gal-1 is expressed at low levels, in HCC its 
expression is dramatically up-regulated[62-66]. The 
transcription start site of Gal-1 gene promoter was 
Gastric cancer
Gastric cells
TGF-β1
Apoptosis
GnTV
Migration
Invasion
Angiogenesis
Cancer-associated
fibroblasts
Fibroblast
Hepatocellular carcinoma
Hepatocytes
Space of disse
HSC
GnTV
Tumor growth
EMT
Migration
GnTV
Proliferation
Migration Activated HSC
Adhesion to
ECM
Angiogenesis
Adhesion to
endothelium
Immune evasion
T-cell
apoptosis
T regs
Colorectal cancer
Colon cells
Adhesion to
ECM
GnTV
Tumor growth
?
Migration
Metastasis
Blood vessel
GnTV
Gal-1
Pancreatic ductal adenocarcinoma
Pancreatic cells
PSC
Migration
Angiogenesis
Blood
vessel
T-cell
apoptosisNeutrophil
Immune
evasionCollagen
Fibrosis
Proliferation
Migration
Invasion
Activated PSC
Tumor growth
Blood vessel Liver sinusoid
GnTV
Figure 2  Proposed models of Galectin-1 contribution to the progression of gastric cancer, hepatocellular carcinoma, colorectal cancer and pancreatic 
ductal adenocarcinoma. Galectin-1 (Gal-1) has key functions in tumor and tumor-associated stromal cells, favoring tumor cell proliferation and dissemination, 
angiogenesis and immunosuppression. A high exposure of Gal-1 glycan partners also contribute to tumor progression. ECM: Extracellular matrix; EMT: Epithelial-
mesenchymal transition; GnTV: β1,6-N-acetylglucosaminyltransferase V; HSC: Hepatic stellate cell; PSC: Pancreatic stellate cell; TGF-β1: Transforming growth factor 
beta 1.
Bacigalupo ML et al . Galectin-1 in gastrointestinal malignancies
5271 August 7, 2017|Volume 23|Issue 29|WJG|www.wjgnet.com
frequently methylated in non-tumor liver, whereas 
it was hypomethylated in HCC tissues[63]. Besides, 
Gal-1 was significantly increased in HCC samples 
from patients with metastasis compared to those 
harboring a non-metastatic primary tumor and it 
was found accumulated in the stroma surrounding 
tumor hepatocytes[64]. Accordingly, Gal-1 was highly 
expressed in stromal α-SMA-positive cells in HCC, 
indicating that Gal-1 is overexpressed in hepatic 
stellate cells (HSCs)[66].
The prognostic value of Gal-1 in HCC patients was 
recently evaluated. Elevated Gal-1 expression in HCC 
was significantly associated with tumor aggressiveness 
(vascular invasion, incomplete encapsulation, poor 
differentiation and large tumor size), dissemination 
and enhanced risk of post-operative recurrence[65]. 
Additionally, high stromal Gal-1 expression in HCC 
was correlated with tumor size, TNM stage and distant 
metastasis and negatively correlated with patient 
prognosis[66]. Moreover, in HCC samples, an inverse 
correlation between miR-22 and Gal-1 expression was 
found[66]. miR-22 is downregulated in HCC[67] and Gal-1 
has been predicted to be a target of miR-22. 
Furthermore, a positive correlation was observed 
between Gal-1 expression and tumor-infiltrating FoxP3+ 
Tregs in HCC tissues[65]. Since Gal-1 is a key regulator 
of CD4+CD25+ Tregs, which in turn play an essential 
role in suppression of anticancer immunity[68], the 
interaction between Gal-1 and Tregs might play a 
role in immunosuppression against HCC. Recently, 
it was shown that patients with advanced HCC had 
significantly higher serum Gal-1 levels than healthy 
volunteers[69]. These elevated serum levels correlated 
with poor treatment efficacy of sorafenib and were an 
independent factor associated with poor progress-free 
survival and overall survival[69]. 
These findings demonstrate that Gal-1 overexpression 
in HCC tissues correlate with tumor aggressiveness 
and support the potential use of Gal-1 as a novel 
predictive and prognostic biomarker of HCC (Figure 1). 
Gal-1 contribution to tumorigenesis, metastasis and 
chemoresistance in HCC experimental models
Gal-1 role in HCC tumor growth and metastasis in vivo 
was evidenced. We found an increase in tumor volume 
and in the number of draining-tumor lymph nodes 
in athymic mice injected with Gal-1-overexpressing 
human HepG2 HCC cells, respect to control mice[70]. 
Recently, Gal-1 involvement in HCC chemoresistance 
was also demonstrated. Cisplatin anti-tumor activity 
was enhanced with the administration of the galectin 
inhibitor thiodigalactoside in a mouse hepatoma 
model[71]. 
Interestingly, a dual role of Gal-1 in liver inflammation 
and tumorigenesis has been dissected in multidrug 
resistant knock-out mice[72]. This is an experimental 
model of inflammation-induced chronic cholestatic 
hepatitis at an early age and HCC at a later age, which 
together mimic the evolution of human disease[73]. 
Gal-1 showed a strain-dependent protective anti-
inflammatory function at early stages delaying HCC 
development. Remarkably, Gal-1 deficiency in knock-
out mice resulted in a significant retardation of liver 
regeneration, evidenced by a delay in hepatocyte 
proliferation, liver mass restoration and macrophage 
recruitment and a decrease in transient liver post-
partial hepatectomy steatosis[74]. 
These findings revealed that Gal-1 controls hepa-
tocarcinogenesis. It may act as a protective anti-
inflammatory agent at early stages of the chronic liver 
pathology, but as a pro-tumorigenic agent at late stages, 
contributing to HCC growth and metastasis (Figure 2).
Functional studies associated with HCC progression, 
dissemination and chemoresistance induced by Gal-1
Gal-1 overexpression observed in HCC human tissues 
was confirmed in cell lines[63,64]. In fact, Gal-1 mRNA 
levels were higher in more invasive and undifferen-
tiated human HCC cell lines as compared to well-
differentiated HCC cells and normal liver cells. Inter-
estingly, a methylation-sensitive factor was essential 
for Gal-1 gene activation in HCC cells[63]. 
Furthermore, the correlation between increased 
expression of Gal-1 in HCC and the presence of 
metastasis was validated by in vitro functional studies. 
Notably, Gal-1 overexpression increased human HuH-7 
HCC cell migration and invasion through Sky receptor 
tyrosine kinase phosphorylation[64]. Next, our studies 
provided evidence of Gal-1 as a glycan-dependent 
modulator of HepG2 cell adhesion and polarization[70]. 
The pro-adhesive effect of Gal-1 was mediated by 
α1, α2, α3, αv and β 1 integrins and PI3K and/or ex-
tracellular signal-regulated kinase (ERK) 1/2 signaling 
pathways[70]. Recently, we also demonstrated that 
increased levels of Gal-1 induced EMT in HCC cells, 
involving PI3K/AKT and WNT/β-catenin proliferative 
signaling pathways[75]. Gal-1 up-regulation in HepG2 
cells induced E-cadherin downregulation and increased 
levels of the transcription factor Snail, one of the main 
inducers of EMT in HCC. Moreover, enhanced Gal-1 
expression favored the transition from an epithelial 
cell morphology toward a fibroblastoid phenotype, 
vimentin up-regulation and resistance to anoikis 
(programmed cell death induced upon cell detachment 
from extracellular matrix)[75]. 
The glycosylation pattern of HCC cells also changes 
during EMT. Particularly, an increase of GnTV-mediated 
β1-6 N-glycan branching and a decrease of α2,6 
sialylation (structure capable of precluding Gal-1 binding) 
were observed in HuH-7 cells undergoing EMT[76]. 
Interestingly, GnTV was increased in high metastatic 
HCC cells as compared to low metastatic cells[77], in 
the liver of a murine model of hepatocarcinogenesis as 
well as in regenerative liver[78]. Further, tetra-antennary 
glycans and GnTV expression were increased in HCC 
samples and positively correlated with TNM stage and 
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impaired clinical outcome in patients[79,80]. Thus, these 
findings suggest that Gal-1-specific glycan epitopes 
are more exposed during HCC cell dissemination.
Regarding HCC cell growth and/or proliferation, 
extracellular Gal-1 (recombinant protein) attenuated 
cell cycle progression and induced apoptosis of HepG2 
cells via interaction with α 5β 1 integrin[81,82]. Remarkably, 
during the early stages of HCC, TGF-β1 acts as a tumor 
suppressor; however in advanced stages, HCC cells 
lose their cytostatic response to this cytokine and 
undergo EMT. Recently, we demonstrated that TGF-β1 
induced Gal-1 expression and secretion by HepG2 
and HuH-7 cells. At the same time, intracellular Gal-1 
modulated HepG2 cell proliferation and sensitivity to 
TGF-β1-induced growth inhibition[83]. Therefore, Gal-1 
and TGF-β1 might function coordinately within the HCC 
microenvironment to regulate tumor growth, invasion 
and metastasis. 
Concerning the interaction between tumor hep-
atocytes and stromal cells, we demonstrated that Gal-1 
secreted from HCC cells promoted human SK-HEP-1 
liver sinusoidal endothelial cell (LSEC) proliferation and 
migration and glycan-dependent HCC cell adhesion 
to LSECs[83]. Also, Gal-1 was augmented in activated 
compared to quiescent rat and human HSCs[66,84] and 
stimulated HSC proliferation and migration through 
carbohydrate-dependent mechanisms via ERK1/2 
signaling pathway[85]. Recently, it was shown that HSC-
derived Gal-1 promoted CD3+ T-cell apoptosis and 
Th1/Th2 cytokine balance skewing[66]. Remarkably, 
miR-22 inhibited Gal-1 expression in HSCs and its 
immunosuppressive function. Furthermore, HSCs 
isolated from HCC tissues exhibited higher Gal-1 
expression and more powerful immunosuppression 
than HSCs derived from normal liver samples[66]. 
As for the role in HCC chemoresistance, Gal-1 
expression and secretion increased in sorafenib-resistant 
HuH-7 cells (HuH-7-R) through the AKT/mammalian 
target of rapamycin (mTOR)/hypoxia inducible factor 
(HIF)-1α pathway. Interestingly, Gal-1 downregulation 
suppressed migratory and invasive abilities of HuH-7-R 
cells and restored sorafenib sensitivity[69]. Besides, Gal-1 
induced chemoresistance to cisplatin in HepG2 and 
HuH-7 cells in a glycan-dependent manner, inhibiting 
AKT/mTOR signaling and triggering autophagy[71]. 
Thus, high levels of Gal-1 in tumor microenvironment 
induce HCC cell proliferation, EMT and dissemination, 
angiogenesis, immunosuppression and chemoresistance 
(Figure 2). Collectively, these findings reveal key roles of 
Gal-1 in HCC progression. Furthermore, Gal-1 represents 
a promising target to confront HCC chemoresistance. 
ROLES OF GAL-1 IN COLORECTAL 
CANCER
Colorectal cancer (CRC) is the fourth cause of cancer-
related deaths[1]. Nowadays, various techniques 
are available to detect CRC as precursor lesions[86]. 
Patients early diagnosed have a 5-year survival rate 
of 90%-95% following surgical resection. However, 
metastasis are present in approximately 20% of 
patients at initial diagnosis[87] and half patients will 
develop metastatic disease[88,89]. When diagnosed at 
advanced stages, treatment consists of a combination 
of surgery, chemotherapy and radiotherapy and the 
5-year survival rate is only 5%-10%[90]. 
The greatest risk factor for CRC is increasing age[89]. 
Sporadic CRC, due to somatic mutations, account 
for about 70% of all cases. Familial CRC, a group of 
diseases harboring familial predisposition to develop 
CRC, is about 10%-30%, whereas hereditary diseases 
are 5%-7%[91]. CRC develops through a gradual 
accumulation of genetic and epigenetic changes, 
leading to the transformation of normal colonic mucosa 
into invasive cancer[86,89]. Some typical activating gene 
mutations arise on members of WNT signaling pathway 
and KRAS oncogene and inactivating mutations occur 
on the TP53 tumor suppressor gene[92]. 
Despite the recent achievements in the understanding 
of colorectal carcinogenesis, the incidence and mortality 
rates highlight the need for new diagnostic markers 
of early disease, an improved understanding of tumor 
progression and the identification of new genes and/or 
pathways contributing to malignancy. 
In this section we analyze the current knowledge on 
the roles of Gal-1 in CRC progression and its potential 
use as therapeutic target.
Gal-1 expression in human CRC tissues, correlation 
with clinical features and potential use as biomarker
Positive Gal-1 expression was detected in CRC 
tissues many years ago, by immunohistochemistry and 
Western blot[93,94]. Gal-1 levels were low in normal and 
neoplastic epithelial cells, but the stroma showed a 
progressive Gal-1 overexpression from normal mucosa 
to adenomas and carcinomas[95]. Gal-1 increase in CRC 
tissues was further confirmed by several studies, but 
discrepancies on Gal-1 localization were found[96-101]. 
Some studies reported marked Gal-1 expression both 
in epithelial and stromal compartments, while others 
emphasized Gal-1 strong expression mainly in stroma. 
In addition, Gal-1 staining was faint in endothelial 
cells of normal tissues but strong in CRC-associated 
endothelium, especially in proliferating endothelial 
cells[15]. 
Concerning the correlation with patient clinical 
features, contradictory results were obtained. Epithelial 
Gal-1 levels in early stage samples were associated with 
short survival[97]. Furthermore, Gal-1 expression was 
related to tumor invasion and lymph node involvement, 
but not to tumor differentiation[98]. However, no 
correlation was found between stromal Gal-1 expression 
and tumor size, stage, differentiation, nor with 
patient survival or relapse-free probability[95]. Hence, 
increasing the number of cases analysed is crucial to 
reach a more reliable conclusion. Gal-1 expression 
was also higher in biopsies from radiotherapy-
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responder patients with rectal cancer than in those 
from nonresponders[102]. Thus, Gal-1 gene expression 
profiling was suggested to be useful in predicting the 
response to radiotherapy.
Some studies focused on the evaluation of circulating 
Gal-1 levels as possible biomarkers or prognosis 
predictors. An increase of plasma Gal-1 levels in CRC 
patients respect to healthy controls was detected. These 
levels were already increased in CRC early stages 
and importantly, were found decreased after patient 
surgery[101]. Also, high serum Gal-1 positively correlated 
with tumor stage and lymph node metastasis[19,103]. 
The expression of accessible binding sites specific 
for Gal-1 (determined by biotinylated Gal-1) increased 
with dysplastic and malignant progression[96]. 
Moreover, the increase in β1,6-branched structures 
in CRC human samples was associated with lymph 
node metastasis and decreased survival rates in CRC 
patients[104]. Accordingly, GnTV overexpressed in CRC 
tissues correlated with metastasis[105]. Remarkably, the 
up-regulation of a novel glycosiltransferase, β3GnT8, 
which can extend polylactosamine on N-glycans, was 
also described in CRC tissues[106]. 
Thus, overexpression of Gal-1 and a high exposure 
of its glycan partners in CRC tissues correlate with 
tumor progression. Further studies are required to 
confirm its potential use as a biomarker for CRC (Figure 1).
Molecular mechanisms associated with CRC cell 
adhesion, migration and growth/proliferation modulated 
by Gal-1
Gal-1 expression was analysed in many cell lines. 
Gal-1 mRNA was detected in normal colon and 
CRC cells, whereas Western blot analysis showed 
variable Gal-1 expression[96,107-109]. Further, when 
global protein expression was analysed in human 
poor and high metastatic CRC cell lines, Gal-1 was 
identified as a protein differentially expressed[110]. 
Mechanisms accounting for gene regulation were also 
studied. Gal-1 expression was induced by sodium 
butyrate, a differentiation-inducing agent and by the 
hypoxia-related transcription factor HIF-1α in CRC 
cells[98,108,111,112]. Interestingly, epigenetic regulation of 
Gal-1 expression was also observed. It was revealed 
that promoter methylation contributes to silencing 
Gal-1 gene transcription in CRC cells[108]. 
The role of Gal-1 and its cell surface glycan partners 
in CRC cell adhesion was evaluated. The inhibitor of 
N-acetyllactosamine synthesis, 2-Acetamido-l,3,6-
tri-O-acetyl-4-deoxy-4-fluoro-a-D-glycopyranose, 
impaired HT-29 cell adhesion to Gal-1. This decreased 
attachment correlated with reduced levels of cell 
surface lysosome-associated membrane proteins 
(LAMP)[113]. Moreover, LAMP-1, LAMP-2 and carci-
noembryonic antigen were identified as the major Gal-
1-binding glycoproteins in CRC cells[112]. Gal-1 was 
capable as well of inducing Colo201 CRC cell adhesion 
to ECM glycoproteins[114]. Moreover, Gal-1 pro-adhesive 
effect was glycan-dependent with the involvement of 
PI3K and mitogen-activated protein kinase signaling 
pathways[114]. Of note, GnTV overexpression in CRC 
cell lines induced resistance to anoikis and WNT 
signaling activation[115]. 
Other Gal-1 roles in CRC cells seem to depend on 
whether the lectin is localized intra- or extracellularly 
and the cell line analysed. A Gal-1-enriched ECM 
decreased HCT-15, LoVo and CoLo201 cell motility[96], 
thus extracellular Gal-1 reduces CRC cell migration. 
Instead, contradictory effects were observed modi-
fying intracellular Gal-1 expression. Silencing Gal-1 
inhibited SW620 cell invasion and migration induced 
by hypoxia[98]. In contrast, Gal-1 up-regulation in 
LS-180 cells significantly decreased cell migration and 
invasion[108]. 
Regarding cell viability, Gal-1 overexpression 
induced Colo201 and LS-180 cell apoptosis[108,114], but 
extracellular Gal-1 had no effect on HCT-15, LoVo, 
DLD-1, HT-29, Caco-2 and Colo201 cell growth[81,96,114]. 
Interestingly, α 5 integrin ectopic expression sensitized 
HT-29 and Caco-2 cells to exogenous Gal-1-induced 
growth inhibition, indicating that Gal-1-α 5 integrin 
interaction attenuated cell cycle progression[81]. 
Further, Gal-1 overexpression induced LS-180 
cell cycle arrest and apoptosis with concomitant 
downregulation of WNT and nuclear factor kappa B 
(NF-κB) signaling pathways[108]. Conversely, Gal-1 
interaction with protocadherin-24 (a non-classical 
cadherin downregulated in CRC cells) enhanced 
Gal-1 retention in HCT116 CRC cell membranes. This 
interaction abolished Gal-1-mediated PI3K activation 
and decreased nuclear β-catenin in cells[116], suggesting 
that protocadherin-24 loss and Gal-1 up-regulation 
may lead to proliferative WNT signaling activation in 
these cells.
These findings show the relevance of Gal-1-glycan 
interaction in CRC cell adhesion and the complexity of 
Gal-1 function in CRC cell migration and growth (Figure 
2). Therefore, further studies are required to decipher 
the mechanisms by which proliferative signaling 
pathways are regulated in CRC cells expressing 
endogenous Gal-1. 
In vivo studies of Gal-1 role in CRC 
Nonsteroidal anti-inflammatory drugs such as 
indomethacin (IN) exert anti-CRC activity via a cy-
clooxygenase-independent mechanism. Oral 
administration of IN significantly suppressed CRC 
growth of HCT116 xenografts in BALB/c-nude mice[117]. 
Of note, by using proteomic tools, it was demonstrated 
that IN downregulated Gal-1 expression in CRC, 
suggesting that IN-anti-proliferative activity against 
this tumor might be related to Gal-1[118]. However, 
the role of Gal-1 in CRC tumor growth still remains 
uncertain. 
Alternatively, GnTV involvement in colon tum-
origenesis was already investigated. Interestingly, 
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GnTV levels in CRC cells injected into nude mice were 
positively associated with tumor growth. Moreover, 
using a CRC murine model (Apcmin/-) with different 
GnTV backgrounds, it was shown that GnTV knock-
out resulted in reduced tumor size, increased animal 
survival and a decrease in colon cancer stem cell 
population. Furthermore, GnTV regulated WNT/β-catenin 
signaling pathway[115]. 
Strikingly, although much research focused on 
Gal-1 expression and function in human CRC tissues 
and cell lines, no confirmation of Gal-1 roles on CRC 
progression was obtained through experimental 
models. Even though extensive studies are required to 
evaluate Gal-1 function in vivo, we can speculate that 
Gal-1 and GnTV may act coordinately to influence CRC 
progression.
ROLES OF GAL-1 IN PANCREATIC CANCER
Pancreatic cancer (PC) is a highly lethal disease, for 
which incidence matches mortality. Pancreatic ductal 
adenocarcinoma (PDAC), the most common type of 
PC, is one of the most aggressive tumors. The overall 
5-year survival rate for this malignancy remains the 
lowest of any cancer (7%), due to limited diagnostic 
methods, disease aggressiveness and lack of targeted 
therapeutic interventions[119]. 
Major risk factor for PC is chronic pancreatitis. 
Tumors often develop from microscopic non-invasive 
epithelial proliferations within the pancreatic ducts, 
referred to as pancreatic intraepithelial neoplasias 
(PanINs)[120]. Mutations in KRAS, CDKN2A and TP53 
oncogenes and in tumor suppressor gene SMAD4 
usually drive to PDAC[121]. Emerging data have high-
lighted the important contribution of tumor stroma 
in PC maintenance, progression and also, in chemo-
therapy resistance[122].
Treatment options have improved throughout 
the last decades. However, surgery remains the 
primary therapy and candidates to this intervention 
represent a very low percentage[121]. Furthermore, 
efficacy of conventional chemoradiotherapy for PDAC 
patients is limited[123]. Hence, a better understanding 
of the mechanisms underlying PC development and 
progression is needed. 
In this section we provide an overview of the 
relevant contribution of Gal-1 to PC progression.
Gal-1 expression in human PC tissues, correlation 
with clinicopathological parameters and prognostic 
significance
Proteomic approaches were applied to identify proteins 
differentially expressed in normal and pathological 
human pancreas. While Gal-1 was undetectable in 
normal pancreas, its expression was up-regulated in 
PC[124-129]. These results, validated by Western blot and 
immunohistochemistry, showed that Gal-1 protein 
expression and staining intensity increased gradually 
from normal pancreas to chronic pancreatitis, PanIN 
lessions and PDAC[125,130-133]. Moreover, Gal-1 expression 
was significantly higher in poorly differentiated PDAC 
tumors compared to well/moderately differentiated 
ones[133,134]. Gal-1 expression was essentially restricted 
to the peritumoral stroma, with low expression within 
the neoplastic epithelium[125,126,131-133]. Concomitantly, 
stromal Gal-1 expression correlated with pancreatic 
fibrosis, a process that can develop cancer[135]. 
Within tumor stroma, Gal-1 was detected in α-SMA 
positive regions (activated pancreatic stellate cells, 
PSCs). Gal-1-expressing PSCs were scattered in 
chronic pancreatitis tissues, but they formed a tight 
fibrotic barrier surrounding the tumor in PC samples. 
Interestingly, CD3+ T cells were found to surround 
malignant cells in PDAC tissues with few infiltrating 
T cells in the tumor parenchyma. These results 
suggested that Gal-1-expressing PSCs can prevent 
CD3+ T cells from infiltrating the pancreatic tumor[132].
Notably, stromal Gal-1 expression in PC tissues was 
associated with an increase in tumor size, lymph node 
metastasis, perineural invasion and differentiation and 
served as an indicator of poor survival[130,134]. Accordingly, 
after quantitative proteomic profiling analysis of PDAC 
tissues, Gal-1 was suggested as a negative predictor 
of PC survival[131].
Thus, high levels of Gal-1, mainly in stroma, play 
fundamental roles early in PC tumorigenesis and 
progression (Figure 1). 
Gal-1 involvement in PC progression in experimental 
models
Transgenic mice overexpressing the oncogene Myc 
under the control of elastase promoter (Ela-myc) 
constitute a well-characterized model of PC[136,137]. In 
tumors from Ela-myc mice, strong Gal-1 expression 
was detected in both epithelial and stromal cells[138,139]. 
Interestingly, Gal-1 depletion in these mice resulted 
in tumor microenvironment remodeling, rendering 
a decrease in tumor proliferation, angiogenesis and 
fibroblasts activation and an increase in T-cell and 
neutrophil infiltration and animal survival. Furthermore, 
levels of transcription factor Gli and Hh receptor 
Patched were reduced in Gal-1-depleted mice[138]. Hh-
Gli pathway is involved in the initiation and progression 
of PDAC. Thus, these findings evidence a critical role of 
Gal-1 in PC development and progression through the 
Hh-Gli pathway. 
Moreover, xenografts of wild-type or Gal-1-depleted 
PC cells injected in nude mice showed no differences 
in tumor progression[138]. Accordingly, implanted PC 
cells produced small tumors, which progressed slowly; 
whereas addition of PSCs to the implanted cancer cells 
resulted in large tumors with quick progression[130]. 
Also, cancer cells implanted with PC-associated 
PSCs exhibiting high levels of Gal-1 developed larger 
tumors, than those that were implanted with PSCs 
from normal pancreas[130]. These results point out the 
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crucial contribution of tumor microenvironment in Gal-1-
induced effects in pancreatic carcinogenesis.
The field of nano-oncology offers the possibility to 
use glycan-based galectin inhibitors or glycan ligand-
based functionalized nanoparticles for diagnostic, 
prognosis and therapeutic purposes[7]. In this regard, 
taking advantage of Gal-1 up-regulation in PC, the 
delivery of magnetic nanoparticles using Gal-1 as a 
target receptor to PC tissues was described[140]. As 
targeting moieties, glycosylated peptides derived from 
tissue plasminogen activator (tPA) were covalently 
attached onto the nanoparticle surfaces[140]. tPA is a 
multifunctional protein overexpressed in PDAC and 
was described as a ligand of Gal-1 in pancreatic 
tissues[139,141]. Through magnetic resonance imaging 
of mouse PANC-1 xenografts, an increased uptake of 
targeted nanoparticles vs non-targeted nanoparticles 
was shown[140]. This result suggests that Gal-1 may 
serve as a strong candidate for PC therapy and opens 
up a window of theranostics (integrated diagnostic 
imaging and therapy) for this disease. 
Functional studies associated with PC progression 
induced by Gal-1 
Gal-1 expression was detected in several PC cell lines. 
During CFPAC-1 cell migration, Gal-1 localized at cell 
membranes, at the migration front[139]. There, it co-
localized with its ligand tPA[139,141]. Gal-1 downregulation 
in CFPAC-1 cells markedly decreased tPA-induced 
ERK1/2 activation, cell proliferation, migration and 
invasion[139]. These findings support a new molecular 
mechanism by which Gal-1 interaction with tPA 
contributes to PDAC progression. In this interaction, 
tPA glycosylation was required. Interestingly, the 
modulation of glycosylation via galectin binding, with 
functional implications, was reported[142-144]. The tumor 
suppressor p16INK4a induced Gal-1 up-regulation 
and increased expression of α 5β 51 integrin at cell 
surfaces. Besides, p16INK4a changed cell glycosylation 
pattern, reducing glycoprotein α2,6 sialylation. As 
a consequence, the susceptibility to carbohydrate-
dependent induction of anoikis was increased through 
Gal-1-α 5β 51 integrin interaction[142-144]. Moreover, the 
downregulation of MUC16, a heavily glycosylated 
type-I transmembrane mucin overexpressed in PDAC 
decreased PC cell adhesion to Gal-1[145]. 
Global analysis of differentially expressed genes 
in control and Gal-1-silenced PANC-1 cells revealed 
that Gal-1 levels correlate with genes involved in cell 
migration, adhesion and malignant transformation and 
with genes of the Hh-Gli axis[138]. Gal-1 downregula-
tion reduced PANC-1 cell migration, motility and 
resistance to anoikis and increased the expression 
of fibronectin-1, integrin-α 5, thrombospondin-1 and 
E-cadherin[138]. Moreover, Gal-1 silencing decreased the 
expression of upstream and downstream effectors of 
Hh-Gli axis both in PC cells and PSCs. On the contrary, 
Gal-1 overexpression in PDAC cells led to increased Gli 
transcriptional activity[138]. 
Interestingly, several studies demonstrated that 
activated PSCs express and secrete high levels of 
Gal-1. The expression of this galectin was higher 
in PSCs isolated from PDAC samples (CaPSCs) 
than those isolated from normal pancreatic tissues 
(NPSCs)[130,132,134,146-149]. Remarkably, Gal-1 knock-down 
in human PSCs reduced cell migration and invasion. 
Besides, exogenous Gal-1 was capable of inducing 
proliferation, collagen synthesis and chemokine 
production in rat PSCs, involving MEK1/2-ERK1/2 
and c-Jun N-terminal kinase signaling pathways and 
transcription factors NF-κB and activator protein-1 
activation[148,149]. Further, Gal-1 expression in PSCs 
was induced by conditioned media from CFPAC-1 PC 
cells[146]. Besides, CFPAC-1 cells co-cultured with PSCs 
showed an increase in MMP-2 and MMP-9 expression 
and a stronger ability to proliferate and invade than 
their counterparts alone. These effects were more 
pronounced in cancer cells co-cultured with CaPSCs 
than those ones with NPSCs and were partially blocked 
in the presence of lactose, a galectin inhibitor[130,146]. 
Furthermore, PSC-derived Gal-1 involvement in tumor 
immunosuppression was reported. Gal-1-overexpression 
in activated PSCs decreased CD3+ T cell viability and 
skewed the cytokine secretion balance towards a Th2 
immune response[132,134].
Altogether, the results discussed herein reveal 
that a coordinated regulation of Gal-1/Gal-1 counter-
receptor expression and glycosylation may lead to 
PC progression. Besides, Gal-1 might mediate the 
crosstalk between PC and the surrounding stroma by 
modulating Hh-Gli signaling pathway, favoring EMT, 
migration and immunosuppression (Figure 2). 
CONCLUSION
The evidence we summarized here reveals the crucial 
contribution of Gal-1 to the pathogenesis of gastrointestinal 
malignancies. Remarkably, increased levels of Gal-1 
in gastrointestinal tumor microenvironment favor 
progression, aggressiveness and metastasis. We 
also highlighted that alterations in Gal-1-specific gly-
coepitopes may be relevant for gastrointestinal cancer 
development. Undoubtedly, further functional studies 
are required. Yet, we are hopeful that researchers will 
get inspired by the findings obtained so far and will join 
efforts to elucidate the fascinating roles of Gal-1 and 
its glycan-partners, in these diseases. Thus, Gal-1-targeted 
therapies could be implemented in future interventions 
in gastrointestinal tumors.  
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